Canada: Pharma In Brief - Federal Court Finds Health Canada Liable To Apotex In Tort Damages

Cases: Apotex Inc. v. Canada (Minister of Health)
Drug: Apo-Trazad (trazodone)  
Nature of cases: Action for damages in tort and breach of contract  
Successful party: Apotex Inc.
Date of decisions: November 18, 2014


Apotex Inc. ("Apotex") had commenced an action for damages, including punitive damages, against Health Canada for its failure to issue a Notice of Compliance ("NOC") for its product Apo-Trazad until the lapse of a period of seven years.

The Federal Court has found that Apotex was entitled to damages in tort, namely for public misfeasance and negligence, but was required to mitigate its damages. The Court also found that Health Canada was liable for breach of a settlement agreement; however this cause of action failed for being time-barred.

Apotex's action was brought on the basis of misfeasance of public office, negligence, misrepresentation whether fraudulent, negligent or innocent, and breach of a settlement agreement. Health Canada's defense was that Apotex's claims were barred by the limitation period, that Apotex had repudiated the settlement, that there was no duty of care owed to Apotex and that Apotex did not mitigate its damages. The Court acknowledged that Apotex was using its Apo-Trazad submission as a test-case for the determination of a regulatory issue, which in part resulted in the seven year delay.

The sole issue at trial was whether Apotex was entitled to damages. This action was bifurcated and the quantification of damages is to be determined at a later date.

The case is important because it demonstrates that although Health Canada can be found liable for its actions respecting the drug approval process, the issue of damages is an economic determination where a claimant must reasonably mitigate its losses, even where a case is brought as a test-case on an issue.


Apotex filed a submission to Health Canada1 on January 25, 1988 for approval to sell its drug Apo-Trazad. Apotex's submission for Apo-Trazad relied on a U.S. reference product. At that time, Health Canada's policies and guidelines on the ability to use a foreign drug reference product to obtain generic drug approval were unclear. Health Canada did not accept the Apo-Trazad submission and required testing against a Canadian reference product unless the U.S. reference product could be "conclusively proven to be identical"2 to the Canadian product.

Apotex brought a judicial review application in August 1990 to compel the Minster to review its trazodone submission and issue an NOC without requiring the use of a Canadian reference product. The parties reached a settlement agreement on November 26, 1990 and the application was discontinued.  Pursuant to the settlement agreement, Apotex submitted further bioavailability data to establish equivalency between the U.S. and Canadian trazodone reference products. When Health Canada continued to refuse to issue the NOC, Apotex filed a second judicial review application on July 17, 1991. This second judicial review was dismissed in January 1993 by Justice MacKay who held that Health Canada's actions were not 'patently unreasonable' so as to allow the Court to intervene.3

Following additional exchanges with Health Canada, and seven years after filing its original submission, Apotex received its NOC for Apo-Trazad on February 28, 1995.

Apotex's claim for damages against Health Canada

Apotex claims damages against Health Canada for lost sales during the period when it should have received an NOC and for the lost ability to be the first generic in the Canadian market for a trazodone product based on Health Canada's failure to issue a NOC until the lapse of an allegedly undue period of seven years. The Court found that it was clear that Apotex wanted to use its Apo-Trazad submission as a test-case to determine the issue of whether a non-Canadian drug product could be used as a reference product for a generic submission.  The Court recognized that Apotex chose this as a test-case and that, "in no way was Apotex the victim that it purports to be."4

Apotex's claims in tort

Misfeasance of public office

There are two elements to the tort of misfeasance of public office: first, there must be a deliberate unlawful conduct by a public officer in his/her capacity or exercise of a public function; and second, the public officer must be aware that the conduct would likely injure the plaintiff. The Court found that in entering into the settlement agreement with Apotex, Health Canada was disingenuous in representing it would receive further submissions after the settlement agreement and misled Apotex into believing that it would review the data on a standard of equivalency. Health Canada was also aware that the delay or refusal to issue a NOC to Apotex would likely cause injury.

The Court concluded that both elements of the tort had been met and that Health Canada is liable to Apotex for committing the tort of misfeasance of public office.


With respect to negligence, the Court held that but-for the settlement agreement, the duty of care owed by Health Canada to Apotex would not exceed that owed to any other pharmaceutical manufacturer. By virtue of the settlement agreement, Health Canada had a special relationship with Apotex to accept and review their submission and demonstrate transparency in the process. The Court did not accept Health Canada's arguments to the contrary, which included that a finding of negligence would create indeterminate liability on the Crown. However, the Court found that a duty of care arose out of the settlement agreement entered into willingly by both parties, and that Health Canada should not be relieved of a finding of negligence.

The Court concluded that Health Canada's refusal to adhere to the equivalency standard set out in the settlement agreement constituted negligence.

Breach of the settlement agreement  

Apotex also claims damages for Health Canada's breach of the settlement agreement. However, Health Canada successfully defended this claim for being brought after the expiry of the limitation period. The applicable limitation period ended six years after the breach of the settlement agreement. Since the Court concluded that Health Canada had breached the settlement agreement almost immediately following its execution on November 26, 1990, as evidenced by correspondence thereafter and throughout 1991, Apotex would have had to have brought its claim for damages in contract before November 1996. As this action was commenced in October 1998, Apotex's claim in contract is extinguished by the limitation period.

Conclusion: damages and mitigation  

Apotex is entitled to damages in tort for the lost sales of Apo-Trazad from the date when it could have reasonably expected to receive its NOC. The Court held that the profits Apotex would have received must be off-set by mitigation of its damages during this period.

The Court determined, based on expert evidence respecting the timing of generic drug approval from 1988 to 1995, that Apotex should have received its NOC for Apo-Trazad on November 26, 1991, one year after the date of the settlement agreement when Health Canada should have reviewed Apotex's submission.

With respect to mitigating its damages, the Court held that Apotex knew it could have conducted tests against a Canadian reference product (as it did with its other product, Apo-Zidovudine, during that time period) and that such testing would have taken three to six months at a cost of $200,000 to $300,000 dollars. The Court recognized that Apotex was using its Apo-Trazad submission as a test-case and noted that "the Court should not view the question of damages and mitigation from the point of view of a party wanting to make a point."5

Damages should be calculated on the basis that Apotex should have received its NOC on November 26, 1991, and should have mitigated its damages by July 2, 1991 (the date that Apotex wrote to Health Canada indicating that it would mitigate damages by conducting further testing using another drug product). This would have resulted in Apotex receiving its NOC by mid-November 1992. The Court accordingly fixed the termination date for the damages period at November 16, 1992. Apotex is also entitled to recover the costs associated with testing against a Canadian reference product. The Court did not award the punitive damages sought by Apotex.

The quantification of damages will be determined at a later date.

Link to decision:

Apotex Inc. v. Canada (Minister of Health), 2014 FC 1087


1. During the relevant period of this proceeding (1988 to 1995), the Health Protection Branch ("HPB") was the name of the bureau of the Ministry of Health responsible for accepting and reviewing drug submissions. In this Pharma in Brief bulletin, we refer to HPB more generally as "Health Canada" as it is known today.

2. 2014 FC 1087 at para 43.

3. Court File No. T-1877-91; reasons of Justice MacKay reported at 59 FTR 85; Apotex appealed the decision of Justice MacKay, but the appeal was withdrawn in 1995 when the NOC for Apo-Trazad issued.

4. 2014 FC 1087 at para 107.

5. 2014 FC 1087 at para 159.

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions